Results 31 to 40 of about 9,744,428 (293)

Epidermal growth factor receptor in glioblastoma

Oncology Letters, 2017
Mutations in the epidermal growth factor receptor (EGFR) are commonly occurring in glioblastoma. Enhanced activation of EGFR can occur through a variety of different mechanisms, both ligand-dependent and ligand-independent. Numerous evidence has suggested that EGFR is overexpressed in most of primary glioblastomas and some of the secondary ...
Xu, Hongsheng, Zong, Hailiang, Ma, Chong, Ming, Xing, Shang, Ming, Li, Kai, He, Xiaoguang, Du, Hai, Cao, Lei   +8 more
openaire   +3 more sources

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

The spatial organization of the epidermal growth factor receptor on the surface of colorectal carcinoma cells [PDF]

, 2017
The discovery of the existence of the cell membrane has led to a search for its organization on a molecular scale. The advent of artificial lipid bilayers and the development of electron microscopy in the 1930’s provided direct visual evidence for the ...
Fournier, Charlotte
core   +1 more source

Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway

Tumor Biology, 2017
Gallbladder cancer has poor prognosis and limited therapeutic options. Arctigenin, a representative dibenzylbutyrolactone lignan, occurs in a variety of plants.
Mingdi Zhang, Shizhong Cai, Bin Zuo, Wei Gong, Zhaohui Tang, Di Zhou, Mingzhe Weng, Yiyu Qin, Shouhua Wang, Jun Liu, Fei Ma, Zhiwei Quan   +11 more
doaj   +1 more source

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

Thoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko   +10 more
doaj   +1 more source

Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population

Balkan Medical Journal, 2017
Aims: Epidermal growth factor receptor mutation analysis in non-small cell lung cancer is important for selecting patients who will receive treatment with tyrosine kinase inhibitors.
Gaye Güler Tezel, Ebru Şener, Çisel Aydın, Sevgen Önder   +3 more
doaj   +1 more source

Analysis of the mechanisms of resistance to Epidermal growth factor receptor inhibitors and development of multiple targeted strategies [PDF]

, 2008
Background. Primary and acquired resistance to selective Epidermal growth factor receptor (EGFR) inhibitors remains the most significant obstacle to the success of these targeted agents in cancer therapy.
Rosa, Roberta
core   +1 more source

The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris

Journal of Cosmetic Dermatology, 2020
AbstractBackgroundEpidermal growth factor receptor inhibitors (EGFRI) used in cancer chemotherapy cause acneiform folliculitis in 70%‐100% of patients in a dose‐dependent manner. Acneiform folliculitis is considered to be caused by an inflammatory process due to follicular hyperkeratosis and subsequently a set of changes both in epidermis and hair ...
Ikbal Esen Aydingoz, Gulsen Tukenmez Demirci, Deniz Agirbasli, Devrim Oz‐Arslan, Guven Yenmis   +4 more
openaire   +4 more sources

Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer

BMC Medical Imaging, 2021
Background Human epidermal growth factor receptor2+ subtype breast cancer has a high degree of malignancy and a poor prognosis. The aim of this study is to develop a prediction model for the human epidermal growth factor receptor2+ subtype (non-luminal ...
Jin Zhou, An-qi Jin, Shi-chong Zhou, Jia-wei Li, Wen-xiang Zhi, Yun-xia Huang, Qian Zhu, Lang Qian, Jiong Wu, Cai Chang   +9 more
doaj   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Technology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM, Yi Hou PhD, Liang-Chen Qi MD   +2 more
doaj   +1 more source